Clinical Trial Update: A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma has completed enrollment, as reported by a China-based tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-directed CAR-T cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED